News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Patient identification Platform And Aprima Announce Strategic Partnership To Improve Clinical Trial Recruitment Efforts



7/25/2017 10:46:55 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs

ROCHESTER, N.Y., July 25, 2017 /PRNewswire/ -- Patient identification Platform (Patient iP), an emerging health data solutions provider to the pharmaceutical and CRO industries, today announced a new partnership with Aprima® Medical Software. Aprima is a leading provider of innovative electronic health records (EHR), practice management and revenue cycle management solutions for medical practices. This collaboration enables the integration of Aprima EHR data and Patient iP's clinical trial matching solution.

The Patient iP solution, recognized by Microsoft Corporation in 2016 as a Health Innovation Award Winner in the category of "Building the Intelligent Cloud Platform," improves the historically manual and time-intensive process of site selection and subsequent patient matching for clinical trial participation. Under the partnership terms, Aprima medical practice customers can choose to have their fully de-identified data processed through Patient iP's matching engine in order to find potential research participants.  Given that nearly 12 million individuals have electronic records in Aprima software, this is a significant opportunity.

It is well known that clinical trials struggle to meet recruitment and enrollment goals, yet the vast majority of adults have never been asked to participate in a trial. With the Patient iP solution, patients can be identified automatically for studies they meet eligibility criteria for based almost solely on their digital medical history. This capability benefits each stakeholder in the drug development process – the site as a result of greater efficiency and throughput; the sponsor thanks to shortened timelines and related financial savings; and, most importantly, the patient who can opt to try a new treatment approach.

"The medical practice environment is complex and as a core solutions provider to so many physician groups, it is imperative we help them stay industry-savvy by introducing them to highly relevant, proven and complementary offerings to their EHR. We at Aprima are particularly interested in arrangements that permit customers to enhance how they deliver medicine and improve their overall revenue picture – our collaboration with Patient iP will drive both of those outcomes," said Aprima COO, Neil Simon.

The current integration model between the two companies leverages CCDA files generated in Aprima which are then seamlessly transmitted to a practice's Patient iP database. A backfill process transfers historical records prior to system utilization, then a nightly batch update ensures that the two solutions stay synchronized so that each and every patient "match" opportunity is flagged based on the latest information on diagnosis, procedures, medications, test results and so forth.

"Many patients have ten plus years of medical history in an electronic system, and with new clinical research studies being released daily, each in need of participants, it is no wonder the recruitment process tends to be slow and frustrating for all involved. This is precisely why Patient IP was launched, to apply the power of data, automation, and analytics to a problem that can't be solved fast enough for many among us," said Michael Margiotta, founder, and CEO, Patient identification Platform. "We are delighted to partner with Aprima and engage with more of their customers seeking to gain deeper insight into their patient populations."

About Patient identification Platform

The patented Patient iP solution bridges many of the most significant and costly gaps encountered when sponsors and contract research organizations conduct clinical trials: timely patient identification and enrollment. Adoption of the Platform enables CROs to streamline operations, helps study sites leverage existing electronic patient health data, and provides life sciences organizations with the speed necessary to achieve first-mover status. In concert, Patient iP's unique technology and expansive Connected Site Network allow for faster development and approval of drugs and therapies, benefiting patients as well given the potential for healthier and longer lives. For more information, visit us at www.patientip.com or follow us on Twitter @PatientIP.    

About Aprima Medical Software, Inc.

Aprima provides innovative electronic health record (EHR), practice management (PM), population health and revenue cycle management (RCM) solutions for medical practices. For nearly two decades, the company has delivered quality solutions that have helped tens of thousands of users enhance patient care and satisfaction, as well as improve their practices' bottom lines. Its EHR/PM solution sets the benchmark for ease-of-use, speed and flexibility, thanks to its single application, single database and customizable design that adapts automatically to individual physician workflows. Aprima has a proven track record of compliance with government initiatives, such as Meaningful Use and ICD-10, has been awarded pre-validation status for NCQA PCMH recognition and has been given the Frost & Sullivan 2017 Award for Product Leadership. The company is based in Richardson, Texas and performs all development, support, implementation and RCM services from within the U.S. To learn more about how Aprima can help your practice, please visit www.aprima.com, call us at 844 4APRIMA or email us at info@aprima.com.

CONTACT
Jen Crowley
jen.crowley@patientip.com

View original content:http://www.prnewswire.com/news-releases/patient-identification-platform-and-aprima-announce-strategic-partnership-to-improve-clinical-trial-recruitment-efforts-300493401.html

SOURCE Patient identification Platform

Related Links

http://www.patientip.com


Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES